MedPath

Respiratory Impact of LA Volume After IS Block

Phase 4
Completed
Conditions
Arthroscopic Surgery of the Shoulder
Extrafascial Interscalene Plexus Brachial Block
Interventions
Registration Number
NCT04726280
Lead Sponsor
Eric Albrecht
Brief Summary

The hypothesis of this study is that a reduced extrafascial volume of local anesthetic for an interscalene brachial plexus block is associated with a lower incidence of diaphragmatic hemiparalysis after an arthroscopic surgery of the shoulder, without any reduction of the analgesic efficacy.

Detailed Description

The hypothesis of this study is that a reduced extrafascial volume of local anesthetic for an interscalene brachial plexus block is associated with a lower incidence of diaphragmatic hemiparalysis after an arthroscopic surgery of the shoulder, without any reduction of the analgesic efficacy.

Our prospective randomized controlled trial will include two parallel groups: a group will receive a volume of 20 mls of ropivacaine 0.75%, while the other group will receive a volume of 10 mls.

All participants will have a preoperative ultrasound-guided interscalene brachial plexus with an extrafascial injection of 10 or 20 mls of ropivacaine 0.75%. In both groups, participants will have an examination of the hemidiaphgragm with the ultrasound, before and 30 min after the block. The respiratory function will also be assessed with a bedside spirometer before and after the block, and at 12 and 24 postoperative hours. During surgery all participants will receive multimodal analgesia inclusive of iv dexamethasone 8 mg, iv magnesium sulfate 40 milligram kg\^2, iv ketorolac 30 milligrams, and iv acetaminophen 1000 milligrams, according to the current practice in our institution. In the postoperative period, Participants will be prescribed an IV pca of morphine.

Assignment to one of these two groups will be done according to a computer-generated list of random numbers, and the sealed envelopes method will be used.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
60
Inclusion Criteria
  • arthroscopic surgery of the shoulder
  • ASA class 1 to 3
  • age more than 18 years old
Exclusion Criteria
  • patient refusal or inability to understand and/or sign the inform consent
  • contraindication for perineural block (allergy to local anesthetics, infection of puncture site, major coagulopathy, sensitive or motor deficiency on the operative side arm
  • chronic alcool abuse
  • opioid drug abuse or under substitution treatment
  • patients known for allergies to paracetamol, non steroidal anti inflammatory drugs, dexamethasone, sulfate magnesium, ondansetron, droperidol, and omeprazole;
  • patients under chronic corticotherapy
  • patients known for malignant hyperthermia;
  • patients with chronic kidney failure (Glomerular Filtration Rate < 20 ml/min)
  • patients with severe pulmonary disease
  • patients with history of neck surgery or radiotherapy on the operative side;
  • pregnancy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
20 ml single-shot injection groupRopivacaine 0.75% Injectable SolutionIn the 20ml group, participants will have an interscalene brachial plexus with an extrafascial injection of 20 ml ropivacaine 0.75% at the level of C5-C6 nerves roots. Participants will also receive multimodal analgesia with injection of dexamethasone 8 mg iv, magnesium sulfate 40 mg kg\^-1 iv, ketorolac 30 mg iv, and acetaminophen 1000 mg iv, according to the current practice in our institution.
10 ml single-shot injectionRopivacaine 0.75% Injectable SolutionIn the 10ml group, participants will have an interscalene brachial plexus with an extrafascial injection of 10 ml ropivacaine 0.75% at the level of C5-C6 nerves roots. Participants will also receive multimodal analgesia with injection of dexamethasone 8 mg iv, magnesium sulfate 40 mg kg\^-1 iv, ketorolac 30 mg iv, and acetaminophen 1000 mg iv, according to the current practice in our institution.
Primary Outcome Measures
NameTimeMethod
Incidence of hemidiaphragmatic paralysis30 minutes after the interscalene plexus brachial extrafascial injection
Secondary Outcome Measures
NameTimeMethod
Duration of motor blockup to 24 hours postsurgery

in minutes

Duration of sensory blockup to 24 hours postsurgery

in minutes

Presence of Dyspneain phase 1 recovery and at 12 and 24 postoperative

Verbal question to the patient if he has dyspnea or not

Installation time of sensory blockup to 30 minutes after the interscalene plexus brachial extrafascial injection

in minutes

Installation time of motor blockup to 30 minutes after the interscalene plexus brachial extrafascial injection

in minutes

Cumulative postoperative iv morphine consumptionin phase 1 recovery and at 12 and 24 postoperative hours

in milligrams

Forced vital capacity30 minutes after the interscalene plexus brachial extrafascial injection, and at 2, 12 and 24 postoperative hours

in liters

Incidence of hemidiaphragmatic paralysisat 2 and 24 postoperative hours
Presence of PONVin phase 1 recovery and at 12 and 24 postoperative

Verbal question to the patient if he has dyspnea or not

Presence of Pruritusin phase 1 recovery and at 12 and 24 postoperative hours

Verbal question to the patient if he has pruritus or not

Presence of Claude-Bernard-Horner syndromein phase 1 recovery and at 12 and 24 postoperative hours

Examination of the patient

Presence of Dysphoniain phase 1 recovery and at 12 and 24 postoperative hours

Verbal question to the patient if he has dysphonia or not

Forced expiratory volume in one second30 minutes after the interscalene plexus brachial extrafascial injection, and at 2, 12 and 24 postoperative hours

in liters per second

Peak expiratory flow30 minutes after the interscalene plexus brachial extrafascial injection, and at 2, 12 and 24 postoperative hours

in liters per second

Time to first dose of postoperative iv morphineup to 24 hours postsurgery

in hours

Pain scores at restin phase 1 recovery and at 12 and 24 postoperative hours

Numeric pain intensity scale. Pain scores range from zero (no pain) to 10 (worst possible pain)

Pain scores on movementin phase 1 recovery and at 12 and 24 postoperative hours

Numeric pain intensity scale. Pain scores range from zero (no pain) to 10 (worst possible pain).

Duration of analgesic blockup to 24 hours postsurgery

in minutes

Satisfaction of the participantsat 24 postoperative hours

Numeric satisfaction intensity scale. Satisfactions range from 0 (totally unsatisfied) to 10 (maximal satisfaction).

Trial Locations

Locations (1)

CHUV (Centre Hospitalier Universitaire Vaudois)

🇨🇭

Lausanne, Vaud, Switzerland

© Copyright 2025. All Rights Reserved by MedPath